Feb 12 (Reuters) - Vertex Pharmaceuticals forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis treatments as well as ...

Vertex stock has climbed more than 60% over three years.

Cystic fibrosis (CF) is the most common inherited metabolic disease in Europe. More than 8,000 people in Germany are affected ...

Please provide your email address to receive an email when new articles are posted on . Few patients with cystic fibrosis have a copy of the 3849+10kb C-to-T splicing mutation. Research is planned to ...

Please provide your email address to receive an email when new articles are posted on . The Cystic Fibrosis Foundation is providing funds to Prime Medicine to advance research on its gene editing ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has approved ...

Just five years ago, starting a family was almost unheard of for patients with cystic fibrosis (CF). And for expectant parents, it was often a huge shock when their child received a diagnosis of CF.

Cystic fibrosis (CF) and pulmonary fibrosis (PF) are two chronic conditions that damage the lungs. Treatment for both aims to improve breathing, manage symptoms, and prevent further lung damage. Your ...

Vertex Pharmaceuticals Incorporated (VRTX) is a good speculative biotech play to look into. That's because it is doing well in the Cystic Fibrosis [CF] space. It will still continue to do well with ...

The work of Dr. Michael J. Welsh and his fellow researchers has improved the quality of life and life expectancy for people with cystic fibrosis. Michael J. Welsh has won the Lasker Award and the 2025 ...

In 1938, Dr. Dorothy Hansine Andersen described a new disease that caused the deaths of children she treated. She called it cystic fibrosis (CF). CF is a genetic condition that occurs due to ...